2[2]Avery GB,Fletcher MA,MacDonald MG.Neonatology pathophysiology & management of the newborn.5th ed.Philadelphia:Lippincott Williams & Wilkins,1999.509
3[5]Lyon A.Chronic lung disease of prematurity:the role of intra-uterine infection.Eur J Pediatr,2000,159:798
4[6]De Dooy JJ,Mahieu LM,Van Bever HP.The role of inflammation in the development of chronic lung disease in neonates.Eur J Pediatr,2001,160:457
5[8]Halliday HL,Ehrenkranz RA,Doyle LW.Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants.Cochrane Database Syst Rev,2003(1):CD001145
6[9]Groneck P.Perinatal glucocorticosteroid therapy:time for reconsideration.Z Geburtshilfe Neonatol,2001,205(6):231
7[10]LeFlore JL,Salhab WA,Broyles RS,et al.Association of antenatal and postnatal dexamethasone exposure with outcomes in extremely low birth weight neonates.Pediatrics,2002,110(2 Pt 1):275
8[1]Wiswell TE.Expanded uses of surfactant therapy.Clin Perinatol,2001,28(3):695
9[2]Findlay RD,Taeusch HW,Walther.Surfactant replacement therapy for meconium aspiration syndrome .Pediatrics,1996,97(1):48
10[3]Lotze A,Mitcbell BR,Bulas DI,et al.Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure.J Pediatr,1998,132:40
9Owen LS, Morley CJ, Davis PG. Neonatal nasal intermit- tent positive pressure ventilation: what do we know in 2007 [J]. Arch Dis Child Fetal Neonatal Ed, 2007,92 (5) : 414-418.
10SaiSunilKishore M, Duma S, Kumar P. Early nasalintermit- tentpositive pressure ventilation versus continuous positive air way pressure for respiratory distress syndrome[J]. Acta Pae- diatr, 2009, 98 (9): 1412-1415.
